BioSpace News Archive

Increase in the prevalence of uterine fibroids in women is anticipated to bolster the growth of the global laparoscopic power morcellators market in coming years.

Chronic infections, autoimmune diseases, pregnancies, and certain cancer types are the some of the secondary triggers of immune thrombocytopenia.

Players and companies in the global healthcare CRO services market are organizations that are contracted by various other companies in order to manage and execute their clinical trials, functions, and other research related duties.

Surge in the data generated by healthcare organizations around the world is likely to push the demand opportunities in the global healthcare data storage market during the forecast period of 2021 to 2031.

Facet joints are connections between bones and spine through which nerve roots pass from spinal cord to the limbs and other parts of the body.

Surge in the utilization of chromatography techniques in R & D activities across various industries such as the pharmaceutical industry is expected to drive the growth opportunities in the global chromatography software market during the forecast period 2021‑2031.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global viral antigens market is expected to grow at a robust pace during the forecast period between 2020 to 2025, predicts Fact.MR.

Genentech, a member of the Roche Group, announced results from an interim analysis of the Phase III HAVEN 6 study, which show Hemlibra® demonstrated a favorable safety profile and effective bleed control in people with moderate or mild hemophilia A without factor VIII inhibitors.

Regeneron Pharmaceuticals, Inc. and Sanofi announced detailed positive Phase 3 results that showed adding Dupixent® to standard-of-care topical corticosteroids significantly improved skin clearance and reduced overall disease severity and itch in infants and children aged 6 months to 5 years with uncontrolled moderate-to-severe atopic dermatitis.

OKYO Pharma Limited is pleased to announce that its drug candidate OK-101 which was developed to treat DED through its anti-inflammatory mode of action also shows potent ocular pain reducing property determined using a mouse model of corneal neuropathic pain, establishing the potential to treat both pain and inflammation, the most common symptoms of dry eye, with a single drug.